Dr. Agarwals Health Care Ltd (AGARWALEYE) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Dr. Agarwals Health Care Ltd. reported strong financial performance for FY25, with total income growing by 27.6% YoY to INR 1,757 crores and revenue from operations up by 28.4% YoY to INR 1,711 crores.
- EBITDA increased by 23.6% to INR 502 crores, with an EBITDA margin of 28.6%. PAT grew by 16% YoY to INR 110 crores, reflecting a PAT margin of 6.3%.
- Growth was driven by new facilities and growth in existing facilities, premiumization of surgeries, increased surgical volumes, and improved surgical conversions.
- Gross profit for FY25 increased by 27.2% to INR 1,368 crores, resulting in a gross margin of 77.9%, driven by strong operational execution and improved material mix.
- Manpower costs rose by 28.4% to INR 574 crores due to strategic hiring and workforce expansion for new facilities. EBITDA margin was slightly impacted by increased other expenses, primarily marketing and one-time expenses.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.